Treatment of Membranoproliferative Glomerulonephritis in Rapidly Progressive Glomerulonephritis
Clinical Scenario
This protocol addresses patients with membranoproliferative glomerulonephritis (MPGN) who present with rapidly progressive glomerulonephritis (RPGN) — a subset that includes both C3 glomerulopathy and primary immune complex MPGN as underlying patterns.
Key Condition
Rapidly progressive glomerulonephritis represents a time-critical presentation. In this context, it may occur against a background of C3 glomerulopathy or primary immune complex MPGN, defining a high-urgency subgroup that requires prompt escalation of treatment.
Patients in this category have generally been excluded from controlled trials, making expert consensus particularly important in guiding management.
Treatment Approach (Partial Overview)
In this rapidly progressive presentation, induction-phase immunosuppression is the cornerstone — with the aim of rapidly reducing active glomerular inflammation. The approach involves intravenous glucocorticoid therapy as part of the initial regimen.
Full regimen, combination details, and sequencing available in the structured protocol below.
References
DOI: 10.1016/j.ekir.2025.10.020
At this stage we can speculate that in patients with rapidly progressive glomerulonephritis, a group excluded from the trials, immunosuppression (e.g., i.v. glucocorticoid therapy; pulse cyclophosphamide therapy) will continue to be used in the induction phase of treatment, with the rationale of rapidly reducing glomerular inflammation.
View source ↗